Anthony D Simon, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Anthony D Simon’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$47,286
Medicare paid this office $47,286 for 221 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 156 | $34,582 | $113 |
| Return visit (30+ min) | 82 | $7,467 | $73 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 57 | $3,422 | $58 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 60 | $1,299 | $13 |
Who their Medicare patients are
221 Original Medicare patients in 2024. Average age 76 · Women 62% · Also on Medicaid 12% · Health risk score 2.34. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Cancer 55% · Diabetes 30% · Coronary heart disease 30% · Chronic kidney disease 29% · Heart failure 20% · Atrial fibrillation 20% · Depression 17% · COPD 10% · Stroke 10% · Dementia 6%.
The office billed $197,489, Medicare allowed $62,451 and paid $47,286; for 585 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 221 | 585 | 76 | 2.34 | $197,489 | $47,286 |
| 2023 | 239 | 536 | 76 | 2.13 | $195,025 | $47,954 |
| 2022 | 198 | 451 | 77 | 2.14 | $147,121 | $34,863 |
| 2021 | 232 | 529 | 76 | 2.37 | $124,094 | $37,318 |
| 2020 | 196 | 373 | 74 | 2.50 | $55,628 | $14,509 |
| 2019 | 220 | 427 | 75 | 2.45 | $35,646 | $20,351 |
| 2018 | 177 | 321 | 74 | 2.40 | $23,986 | $13,376 |
| 2017 | 143 | 239 | 75 | 2.25 | $20,590 | $9,068 |
| 2016 | 46 | 56 | 71 | 2.21 | $8,787 | $2,843 |
| 2015 | 17 | 18 | 71 | 1.64 | $3,648 | $1,178 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 168 | $35,474 | $108 |
| Return visit (30+ min) | 86 | $8,213 | $71 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 56 | $3,214 | $55 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $616 | $25 |
2022: 4 services
| Return visit (30+ min) | 97 | $14,967 | $72 |
| Long return visit (40+ min) | 96 | $13,404 | $113 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 56 | $3,288 | $59 |
| Short return visit (20+ min) | 51 | $3,127 | $47 |
2021: 4 services
| Return visit (30+ min) | 116 | $22,987 | $78 |
| Long return visit (40+ min) | 50 | $6,056 | $116 |
| Short return visit (20+ min) | 104 | $5,375 | $40 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 42 | $2,659 | $62 |
2020: 2 services
| Short return visit (20+ min) | 187 | $12,954 | $38 |
| Return visit (30+ min) | 19 | $1,155 | $55 |
2019: 2 services
| Return visit (30+ min) | 119 | $12,441 | $60 |
| Short return visit (20+ min) | 142 | $7,481 | $35 |
2018: 2 services
| Short return visit (20+ min) | 141 | $8,255 | $36 |
| Return visit (30+ min) | 62 | $4,763 | $57 |
2017: 3 services
| Short return visit (20+ min) | 117 | $7,137 | $37 |
| Return visit (30+ min) | 19 | $1,186 | $59 |
| Short return visit | 21 | $406 | $18 |
2016: 2 services
| Short return visit (20+ min) | 25 | $1,084 | $37 |
| Return visit (30+ min) | 12 | $728 | $52 |
Medicaid work
$253 in 2020
Medicaid paid $253 for 14 billed services this clinician did in 2020, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 14 | $253 |
| 2020 | 14 | 1 | 12 | $253 |
Drugs they prescribed that Part D paid
$1,879,251
Pharmacies billed $1,879,251 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (31 of 1,054) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
808 generic and fewer than 11 brand-name prescriptions · $1,879,251 in drug cost · 20 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 14 | $272,094 | $19,435 |
| Tagrisso | 14 | $233,579 | $16,684 |
| Imbruvica | 12 | $190,050 | $15,837 |
| Eliquis | 54 | $42,756 | $792 |
| Neupogen | 11 | $40,879 | $3,716 |
See all 28 drugs
| Revlimid | 14 | $272,094 | $19,435 |
| Tagrisso | 14 | $233,579 | $16,684 |
| Imbruvica | 12 | $190,050 | $15,837 |
| Eliquis | 54 | $42,756 | $792 |
| Neupogen | 11 | $40,879 | $3,716 |
| Creon | 12 | $23,885 | $1,990 |
| Exemestane | 34 | $12,965 | $381 |
| Xarelto | 20 | $12,467 | $623 |
| Potassium Chloride | 18 | $4,759 | $264 |
| Anastrozole | 129 | $3,726 | $29 |
| Letrozole | 74 | $2,707 | $37 |
| Acyclovir | 36 | $767 | $21 |
| Gabapentin | 22 | $711 | $32 |
| Tamsulosin | 20 | $483 | $24 |
| Dexamethasone | 27 | $373 | $14 |
| Hydroxyurea | 11 | $346 | $31 |
| Omeprazole | 12 | $216 | $18 |
| Hydrocodone-Acetaminophen | 12 | $208 | $17 |
| Escitalopram | 14 | $201 | $14 |
| Ondansetron | 27 | $196 | $7 |
| Ondansetron Odt | 11 | $176 | $16 |
| Pantoprazole | 19 | $173 | $9 |
| Prednisone | 19 | $77 | $4 |
| Diltiazem 24hr Er (Xr) | 13 | $75 | $6 |
| Alendronate | 19 | $52 | $3 |
| Furosemide | 20 | $40 | $2 |
| Lorazepam | 13 | $25 | $2 |
| Cyanocobalamin | 13 | $9 | $1 |
Year by year
| 2024 | 1,054 | 262 | 3% (31) | None | $1,879,251 |
| 2023 | 1,227 | 319 | 7% (84) | None | $2,993,605 |
| 2022 | 1,146 | 300 | 6% (63) | None | $2,414,800 |
| 2021 | 1,146 | 311 | 6% (66) | 25% | $1,862,580 |
| 2020 | 980 | 269 | 5% (49) | 25% | $1,388,312 |
| 2019 | 519 | 208 | 6% (32) | 22% | $508,697 |
| 2018 | 202 | 84 | 17% (35) | 14% | $84,702 |
| 2017 | 111 | 45 | 24% (27) | 10% | $20,729 |
| 2016 | 91 | 33 | 21% (19) | None | $4,635 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Revlimid | 33 | $645,548 | $19,562 |
| Tagrisso | 24 | $438,957 | $18,290 |
| Pomalyst | 15 | $335,999 | $22,400 |
| Jakafi | 11 | $281,833 | $25,621 |
| Lenalidomide | 13 | $222,224 | $17,094 |
| Erleada | 12 | $182,032 | $15,169 |
| Imbruvica | 11 | $170,561 | $15,506 |
| Xarelto | 28 | $37,015 | $1,322 |
| Eliquis | 33 | $28,059 | $850 |
| Abiraterone Acetate | 18 | $16,902 | $939 |
| Exemestane | 30 | $15,289 | $510 |
| Enoxaparin | 12 | $11,006 | $917 |
| Anastrozole | 108 | $4,236 | $39 |
| Potassium Chloride | 17 | $3,492 | $205 |
| Letrozole | 59 | $3,248 | $55 |
| Gabapentin | 53 | $1,561 | $29 |
| Acyclovir | 44 | $1,471 | $33 |
| Hydroxyurea | 36 | $1,446 | $40 |
| Hydrocodone-Acetaminophen | 28 | $576 | $21 |
| Mirtazapine | 13 | $542 | $42 |
| Dexamethasone | 23 | $530 | $23 |
| Pantoprazole | 18 | $472 | $26 |
| Venlafaxine Hcl Er | 13 | $451 | $35 |
| Warfarin | 19 | $424 | $22 |
| Levothyroxine | 11 | $312 | $28 |
| Diphenoxylate-Atropine | 14 | $300 | $21 |
| Allopurinol | 19 | $276 | $15 |
| Ondansetron Odt | 11 | $251 | $23 |
| Tamsulosin | 15 | $214 | $14 |
| Oxycodone | 17 | $208 | $12 |
| Furosemide | 32 | $199 | $6 |
| Alendronate | 18 | $185 | $10 |
| Ondansetron | 13 | $156 | $12 |
| Tramadol | 16 | $149 | $9 |
| Lorazepam | 23 | $143 | $6 |
| Trazodone | 11 | $117 | $11 |
| Oxycodone-Acetaminophen | 11 | $87 | $8 |
| Prednisone | 11 | $75 | $7 |
2022: 32 drugs
| Tagrisso | 47 | $785,862 | $16,720 |
| Revlimid | 24 | $478,052 | $19,919 |
| Jakafi | 15 | $258,230 | $17,215 |
| Xarelto | 20 | $22,718 | $1,136 |
| Eliquis | 29 | $19,620 | $677 |
| Imatinib Mesylate | 19 | $19,391 | $1,021 |
| Enoxaparin | 15 | $8,945 | $596 |
| Exemestane | 36 | $7,816 | $217 |
| Entecavir | 19 | $4,944 | $260 |
| Potassium Chloride | 20 | $3,525 | $176 |
| Letrozole | 63 | $3,278 | $52 |
| Klor-Con | 16 | $3,174 | $198 |
| Anastrozole | 122 | $3,024 | $25 |
| Megestrol Acetate | 16 | $1,660 | $104 |
| Ondansetron | 31 | $1,456 | $47 |
| Gabapentin | 40 | $1,199 | $30 |
| Hydroxyurea | 28 | $1,188 | $42 |
| Diphenoxylate-Atropine | 12 | $900 | $75 |
| Hydrocodone-Acetaminophen | 30 | $619 | $21 |
| Tamoxifen Citrate | 13 | $610 | $47 |
| Acyclovir | 18 | $586 | $33 |
| Warfarin | 27 | $527 | $20 |
| Levothyroxine | 15 | $495 | $33 |
| Dexamethasone | 15 | $370 | $25 |
| Venlafaxine Hcl Er | 17 | $357 | $21 |
| Lactulose | 11 | $285 | $26 |
| Oxycodone | 16 | $245 | $15 |
| Prednisone | 20 | $229 | $11 |
| Dicyclomine | 11 | $204 | $19 |
| Diclofenac | 11 | $146 | $13 |
| Furosemide | 15 | $106 | $7 |
| Lorazepam | 15 | $31 | $2 |
2021: 32 drugs
| Jakafi | 21 | $296,412 | $14,115 |
| Tagrisso | 15 | $238,832 | $15,922 |
| Ibrance | 13 | $184,666 | $14,205 |
| Imbruvica | 11 | $158,163 | $14,378 |
| Lonsurf | 11 | $119,201 | $10,836 |
| Imatinib Mesylate | 17 | $30,701 | $1,806 |
| Eliquis | 33 | $23,781 | $721 |
| Xarelto | 28 | $18,427 | $658 |
| Enoxaparin | 22 | $12,058 | $548 |
| Exemestane | 34 | $4,935 | $145 |
| Anastrozole | 141 | $4,811 | $34 |
| Letrozole | 59 | $3,099 | $53 |
| Hydroxyurea | 27 | $1,596 | $59 |
| Potassium Chloride | 14 | $1,463 | $105 |
| Tamoxifen Citrate | 28 | $1,222 | $44 |
| Gabapentin | 46 | $961 | $21 |
| Venlafaxine Hcl Er | 15 | $633 | $42 |
| Diphenoxylate-Atropine | 13 | $519 | $40 |
| Levothyroxine | 15 | $502 | $33 |
| Pantoprazole | 26 | $487 | $19 |
| Dexamethasone | 17 | $465 | $27 |
| Ondansetron | 22 | $462 | $21 |
| Hydrocodone-Acetaminophen | 28 | $440 | $16 |
| Allopurinol | 21 | $356 | $17 |
| Tamsulosin | 11 | $340 | $31 |
| Oxycodone | 14 | $276 | $20 |
| Prednisone | 26 | $187 | $7 |
| Simvastatin | 11 | $176 | $16 |
| Trazodone | 12 | $174 | $15 |
| Warfarin | 13 | $137 | $11 |
| Lorazepam | 23 | $50 | $2 |
| Tramadol | 12 | $28 | $2 |
2020: 25 drugs
| Tagrisso | 30 | $487,857 | $16,262 |
| Zytiga | 16 | $174,976 | $10,936 |
| Xarelto | 34 | $24,573 | $723 |
| Abiraterone Acetate | 11 | $17,846 | $1,622 |
| Eliquis | 21 | $16,808 | $800 |
| Exemestane | 26 | $6,039 | $232 |
| Anastrozole | 98 | $3,276 | $33 |
| Hydroxyurea | 23 | $1,152 | $50 |
| Letrozole | 29 | $1,127 | $39 |
| Tamoxifen Citrate | 23 | $1,076 | $47 |
| Gabapentin | 42 | $816 | $19 |
| Levothyroxine | 29 | $623 | $21 |
| Potassium Chloride | 14 | $513 | $37 |
| Warfarin | 25 | $465 | $19 |
| Ondansetron | 28 | $416 | $15 |
| Duloxetine | 15 | $408 | $27 |
| Oxycodone | 17 | $381 | $22 |
| Venlafaxine Hcl Er | 21 | $359 | $17 |
| Hydrocodone-Acetaminophen | 21 | $357 | $17 |
| Prednisone | 29 | $263 | $9 |
| Diphenoxylate-Atropine | 15 | $187 | $12 |
| Prochlorperazine Maleate | 11 | $153 | $14 |
| Lorazepam | 16 | $78 | $5 |
| Paroxetine | 13 | $56 | $4 |
| Diazepam | 11 | $52 | $5 |
2019: 10 drugs
| Ibrance | 15 | $184,945 | $12,330 |
| Vimpat | 15 | $10,425 | $695 |
| Eliquis | 11 | $6,482 | $589 |
| Exemestane | 16 | $4,692 | $293 |
| Anastrozole | 54 | $1,563 | $29 |
| Potassium Chloride | 14 | $1,000 | $71 |
| Gabapentin | 45 | $994 | $22 |
| Letrozole | 25 | $841 | $34 |
| Hydrocodone-Acetaminophen | 13 | $176 | $14 |
| Ondansetron | 16 | $105 | $7 |
2018: 5 drugs
| Tamoxifen Citrate | 12 | $560 | $47 |
| Anastrozole | 23 | $344 | $15 |
| Hydrocodone-Acetaminophen | 23 | $201 | $9 |
| Gabapentin | 14 | $114 | $8 |
| Cephalexin | 13 | $68 | $5 |
2017: 2 drugs
| Cephalexin | 11 | $73 | $7 |
| Hydrocodone-Acetaminophen | 11 | $59 | $5 |
2016: 2 drugs
| Levetiracetam | 11 | $488 | $44 |
| Hydrocodone-Acetaminophen | 12 | $205 | $17 |
Money from drug and device companies
$43 in 2025
| 2025 | 2 | 2 | None | $43 |
| 2024 | 2 | 2 | None | $152 |
| 2023 | 1 | 1 | None | $19 |
| 2022 | 1 | 1 | None | $16 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $18 | 1 payment
|
See all 2 published payments
| Daiichi Sankyo | Meals · 2025-09-23 | Enhertu | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Enhertu | $18 |
See earlier years (2024, 2023, 2022)
2024: $152
| Smith+Nephew | Bone Anchors With Arthroscopic Delivery System | $129 | 1 payment
|
| Hologic Sales and Service | Acessa Provu System | $23 | 1 payment
|
2023: $19
| GlaxoSmithKline | Ojjaara | $19 | 1 payment
|
2022: $16
| Hologic | Myosure Tissue Removal Device | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1831597228
- Licence
- CA 95001584
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2100X (363LA2100X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-12-17
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.